RXII:NASDAQ

RXi Pharmaceuticals Corp.

RXi Pharmaceuticals Corporation is a clinical-stage company developing innovative therapeutics that address significant unmet medical needs. Building on the pioneering discovery of RNAi, the Company's discovery and clinical development programs are based on its proprietary self-delivering RNAi (sd-rxRNA®) platform and Samcyprone™, a small molecule topical immunomodulator. Current clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone™ for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. RXi's robust pipeline, coupled with an extensive patent portfolio, provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas. We are committed to being a partner of choice for academia, small companies, and large multinationals. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities, to advance and further develop strategic areas of interest.
RXII:NASDAQ

Expert Comments:

By securing an exclusive option to acquire MirImmune Inc., RXi Pharmaceuticals has expanded its reach into the "high-value" field of immuno-oncology, a move that has energized the company and prompted a pair of analysts to express optimism about RXi's future.
read more >
Maxim Jacobs, Edison Investment Research (10/25/16)
"RXi Pharmaceuticals Corp. recently announced that it has entered into an exclusive option agreement to acquire MirImmune, an early-stage private company focusing on immune checkpoint modulation, in exchange for a share amount equal to 19.99% of RXi's outstanding stock plus milestones. . .MirImmune had licensed RXi's sd-rxRNA technology for use in cell-based cancer immunotherapy back in March 2015. . .the knockdown of these proteins should enable the CAR-T cells to recognize and engage tumor cells that are otherwise masked from the immune system via expression of checkpoint ligands."

Keith Markey, Griffin Securities (10/12/16)
"RXi Pharmaceuticals Corp. takes an exclusive option to acquire MirImmune, a privately held company that licensed RXi's self-delivering RNAi technology for cancer indications in early 2015. Execution of the option, which expires on April 5, 2017, would add six sd-rxRNA compounds to the company's pipeline in exchange for equity stake of 19.99% at the closing. . .the acquisition is an attractive opportunity. . .in 2018, clinical development of the oncology-related compounds should commence. . .2016 will likely close in fine fashion."

Keith Markey, Griffin Securities (8/22/16)
"RXi Pharmaceuticals Corp. will report results from human tests of four programs in the next 12 months or so. . .investors will see data from three clinical trials and a proof-of-concept study of a consumer product. Interim data on Samcyprone should be available in November. . .dermal scarring trial of RXI-109 will report results before year end. . .proof-of-concept results on RXI-231 will likely be available next summer. . .news from the R&D pipeline should pique investors’ interest in RXII shares in the months ahead."

Carol Werther, H.C. Wainwright & Co. (6/7/16)
"We Are Assuming Coverage With a Buy Rating. . .RXi Pharmaceuticals Corp.'s RXI-109 is the basis for our recommendation and in our opinion may reach the US market in 2021. . .the discovery of RNAi is regarded as a significant advancement in the scientific community, and in 2006 the Nobel Prize in Medicine was awarded to the co-discoverers of RNAi, including Dr. Craig Mello, one of the founders of RXI and the Chairman of the Scientific Advisory Board. . .we believe RXII shares are undervalued given the compelling RX-109 results in hypertrophic scarring."

Maxim Jacobs, Edison Investment Research (4/18/16)
"RXi Pharmaceuticals Corp. continues to make solid progress with its 18 April 2016 development pipeline. We anticipate one of two promising cosmeceutical candidates to enter human testing this year. . .we also expect data in H216 in all lead projects including RXI-109 in dermal scarring and in retinal scarring in wet AMD, and Samcyprone in cutaneous warts. . .we also look forward to full enrolment and early read outs this year from a Phase II study with Samcyprone in cutaneous warts. RXi recently initiated a Phase I/II trial in retinal scarring associated with wet-age macular generation, a potentially multi-billion dollar market."

Mark Breidenbach, H.C. Wainwright & Co. (3/31/16)
"RXi Pharmaceuticals Corp. initiated two new clinical studies in 4Q15 and added two extended dosing cohorts to the ongoing 1402 study of RXI-109 in hypertrophic scarring. RXI-109 also entered the 1501 study in retinal scarring associated with age related macular degeneration (AMD), and the company's immunomodulatory gel Samcyprone entered the 1502 study in cutaneous warts. . .we view the recent diversification of RXi's clinical pipeline favorably. . .we believe RXi Pharmaceuticals represents an underappreciated innovator with upside for the long-term investor."

More Expert Comments

Experts Following This Company

Mark Breidenbach – H.C. Wainwright & Co.
Maxim Jacobs – Edison Investment Research
Keith Markey, Scientific Director – Griffin Securities
Carol Werther – Summer Street Research Partners

The information provided above is from analysts, newsletters, the company and other contributors.

RXi Pharmaceuticals Corp. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
RXi has developed a robust, proprietary RNAi therapeutic platform
 
RNAi has the ability to “silence” a specific gene in a disease condition
 
Extensive patent estate provides for multiple development and commercialization of RNAi therapeutics
catalyst Calendar